February 15, 2023: NCHR testified before the Maryland House Environment Committee to support HB299, which would require transparency about the use and disposal of artificial turf and infill. That will enable communities to make informed decisions about the environmental and health impact of these materials.
Read More »Author: Caroline Bradford
Testimony of Dr. Diana Zuckerman at CMS MEDCAC Meeting On Coverage with Evidence Development
February 13, 2023: In testimony before CMS MEDCAC, NCHR strongly supported the new proposals to improve the quality of research needed to decide Medicare coverage evidence. We especially appreciate the focus on clinically meaningful benefits for patients that are representative of Medicare beneficiaries
Read More »American women still can’t get birth control pills without a prescription. This company has been trying for nine years to change that
FORTUNE, February 10, 2023: A company wants their birth control pill to be available over the counter. Is it safe enough to use without a prescription? It is safer than most hormonal contraceptives, but would this set a dangerous precedent for less safe contraceptives?
Read More »Testimony of Dr. Diana Zuckerman About Jemperli (Dostarlimab) FDA Advisory Committee Meeting
February 9, 2023: Dr. Diana Zuckerman of NCHR urges the FDA Oncology Advisory Committee to require randomized trials of Jemperli for rectal cancer instead of single arm trials, so that patients and physicians can make informed decisions about the best treatment.
Read More »NCHR Comments on USPTO-FDA Collaboration and Engagement
February 6, 2023: NCHR’s public comments strongly support FDA’s decision to prioritize USPTO-FDA collaboration. Access to generic drugs and biosimilars is critically important and abuse of the patent system remains a major barrier. We are hopeful that meaningful collaboration between the FDA and the USPTO will result in substantial improvements.
Read More »